Revision of the General USP Chapter <1010>
Recommendation
13-15 October 2026
Barcelona, Spain
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the Pharmacopoeial Forum 40(3) the In-process-revision of the general USP Chapter <1010> - Analytical Data - Interpretation and Treatment - was announced. This revision was suggested due to the proposals the USP received for this capter.
The part on the use of USP reference substances now also describes more detailed the handling of secondary standards which can be traced back to the USP reference standards.
Further, in the entire document the term "method" was replaced by the term "procedure" as far as the description of analytical testing is concerned. This was done in adapting the document to today's USP terminology.
In addition there will be a new Appendix F in which a new statistical test is described for the evaluation of the equivalence of analytical procedures.
Please see the chapter <1010> - Analytical Data - Interpretation and Treatment for further information.
Source: USP - http://www.usp.org
Related GMP News
05.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
05.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence